The Valley of Death in anticancer drug development: a reassessment

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Recent decades show significant progress in understanding cancer biology and identifying potential therapeutic targets.
• However, a high failure rate (approaching 90%) persists in translating these discoveries into effective anticancer therapies, a challenge known as the 'Valley of Death'.

Purpose of the Study:

• To re-evaluate the persistent challenges in anticancer drug development.
• To identify potentially overlooked factors contributing to the high failure rate in clinical translation.
• To propose feasible alternative strategies for improving anticancer drug development.

Main Methods:

• Review and synthesis of current perspectives on the 'Valley of Death' in anticancer drug development.
• Analysis of critical, yet often underemphasized, aspects of tumor physiology, drug pharmacokinetics, preclinical models, drug delivery, and clinical translation.

Main Results:

• The high failure rate in anticancer drug development may stem from overlooking fundamental aspects of cancer biology and drug action.
• Key areas such as tumor microenvironment, drug metabolism, and the predictive validity of preclinical models require greater emphasis.

Conclusions:

• Addressing the 'Valley of Death' requires a renewed focus on fundamental scientific and logistical challenges in drug development.
• Integrating a deeper understanding of tumor physiology and optimizing preclinical models are crucial for successful clinical translation of novel anticancer agents.